Page 17 - Core One News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Core One Labs Provides Clarification on Trading Activity ACCESSWIRE VANCOUVER, BC / ACCESSWIRE / May 21, 2021 / Core One Labs Inc. (CSE:COOL)(OTC PINK:CLABF)(Frankfurt:LD62, WKN:A2P8K3) (the ' Company' or ' Core One'). This news release is issued at the request of the Investment Industry Regulatory Organization of Canada (' IIROC') and the Canadian Securities Exchange (' CSE'). Statements made in the news release issued by the Company on May 4, 2021 indicated that the Company had been made aware of potentially manipulative trading activity in its common shares. The news release issued on May ...

Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD62, WKN: A2P8K3) (the “ Company” or “ Core One”) is pleased to announce it has appointed Dr. Santiago Ferro, Chief Executive Officer of Akome Biotech Ltd. (“ Akome”), as Chief Medical Officer of the Company. Dr. Ferro will lead the Company through clinical trials and commercialization of its psychedelic products. Dr. Ferro is a graduate of Javeriana University Medical School in his native Bogotá, Colombia, where he specialized in Internal Medicine, and received his sub-specialty training in Infectious Diseases at Univers...

Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD62, WKN: A2P8K3) (the “ Company” or “ Core One”) is pleased to announce it has appointed Dr. Santiago Ferro, Chief Executive Officer of Akome Biotech Ltd. (“ Akome”), as Chief Medical Officer of the Company. Dr. Ferro will lead the Company through clinical trials and commercialization of its psychedelic products. Dr. Ferro is a graduate of Javeriana University Medical School in his native Bogotá, Colombia, where he specialized in Internal Medicine, and received his sub-specialty training in Infectious Diseases at Univers...

Published: May 05, 2021 Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD62, WKN: A2P8K3) (the “ Company” or “ Core One”) is pleased to announce it has appointed Dr. Santiago Ferro, Chief Executive Officer of Akome Biotech Ltd. (“ Akome”), as Chief Medical Officer of the Company. Dr. Ferro will lead the Company through clinical trials and commercialization of its psychedelic products. Dr. Ferro is a graduate of Javeriana University Medical School in his native Bogotá, Colombia, where he specialized in Internal Medicine, and received his sub-specialty training in In...

VANCOUVER, British Columbia, May 04, 2021 (GLOBE NEWSWIRE) — Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD62, WKN: A2P8K3) (the “Company” or “Core One”) a biotechnology research and development life sciences enterprise focused on advancing psychedelic medicines to market, is pleased to announce that it has completed the acquisition (the “Transaction”) of Akome Biotech Ltd. (“Akome”). With this strategic acquisition, the scope of Core One’s psychedelics’ bio-pharma research and development division will broaden to include drug formulations that effectively...